OPKO Health, Inc. announced the launch of the 4Kscore test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S. and European launch of the 4Kscore test in 2014. The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer.

The test was developed and validated by OPKO in a 1,012 patient blinded, prospective study in the United States in 2014.